164 related articles for article (PubMed ID: 29317112)
1. Cannabinoid Disposition After Human Intraperitoneal Use: AnInsight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer.
Lucas CJ; Galettis P; Song S; Solowij N; Reuter SE; Schneider J; Martin JH
Clin Ther; 2018 Sep; 40(9):1442-1447. PubMed ID: 29317112
[TBL] [Abstract][Full Text] [Related]
2. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.
Vandrey R; Herrmann ES; Mitchell JM; Bigelow GE; Flegel R; LoDico C; Cone EJ
J Anal Toxicol; 2017 Mar; 41(2):83-99. PubMed ID: 28158482
[TBL] [Abstract][Full Text] [Related]
4. Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ
Newmeyer MN; Swortwood MJ; Andersson M; Abulseoud OA; Scheidweiler KB; Huestis MA
Clin Chem; 2017 Mar; 63(3):647-662. PubMed ID: 28188235
[TBL] [Abstract][Full Text] [Related]
5. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part II: comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents.
Manwell LA; Ford B; Matthews BA; Heipel H; Mallet PE
J Pharmacol Toxicol Methods; 2014; 70(1):112-9. PubMed ID: 24956154
[TBL] [Abstract][Full Text] [Related]
6. Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.
Newmeyer MN; Swortwood MJ; Barnes AJ; Abulseoud OA; Scheidweiler KB; Huestis MA
Clin Chem; 2016 Dec; 62(12):1579-1592. PubMed ID: 27899456
[TBL] [Abstract][Full Text] [Related]
7. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol.
Hartman RL; Brown TL; Milavetz G; Spurgin A; Gorelick DA; Gaffney G; Huestis MA
Clin Chem; 2015 Jun; 61(6):850-69. PubMed ID: 26019183
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of cannabinoids.
Grotenhermen F
Clin Pharmacokinet; 2003; 42(4):327-60. PubMed ID: 12648025
[TBL] [Abstract][Full Text] [Related]
9. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents.
Manwell LA; Charchoglyan A; Brewer D; Matthews BA; Heipel H; Mallet PE
J Pharmacol Toxicol Methods; 2014; 70(1):120-7. PubMed ID: 24973534
[TBL] [Abstract][Full Text] [Related]
10. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.
Deiana S; Watanabe A; Yamasaki Y; Amada N; Arthur M; Fleming S; Woodcock H; Dorward P; Pigliacampo B; Close S; Platt B; Riedel G
Psychopharmacology (Berl); 2012 Feb; 219(3):859-73. PubMed ID: 21796370
[TBL] [Abstract][Full Text] [Related]
11. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations.
Huestis MA; Elsohly M; Nebro W; Barnes A; Gustafson RA; Smith ML
Ther Drug Monit; 2006 Aug; 28(4):540-4. PubMed ID: 16885722
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study.
Pellesi L; Licata M; Verri P; Vandelli D; Palazzoli F; Marchesi F; Cainazzo MM; Pini LA; Guerzoni S
Eur J Clin Pharmacol; 2018 Nov; 74(11):1427-1436. PubMed ID: 29980818
[TBL] [Abstract][Full Text] [Related]
13. Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations.
Anderson LL; Etchart MG; Bahceci D; Golembiewski TA; Arnold JC
Sci Rep; 2021 Jul; 11(1):14948. PubMed ID: 34294753
[TBL] [Abstract][Full Text] [Related]
14. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
16. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics.
Badowski ME
Cancer Chemother Pharmacol; 2017 Sep; 80(3):441-449. PubMed ID: 28780725
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of cannabinoids.
McGilveray IJ
Pain Res Manag; 2005; 10 Suppl A():15A-22A. PubMed ID: 16237477
[TBL] [Abstract][Full Text] [Related]
19. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH).
Huestis MA; Henningfield JE; Cone EJ
J Anal Toxicol; 1992; 16(5):283-90. PubMed ID: 1338216
[TBL] [Abstract][Full Text] [Related]
20. Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and Other Cannabinoids in Arrested Drivers Versus Deceased Drivers.
Lemos NP; San Nicolas AC; Volk JA; Ingle EA; Williams CM
J Anal Toxicol; 2015 Oct; 39(8):588-601. PubMed ID: 26378132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
